Connect with us

Hi, what are you looking for?

Investing

Nektar Regains Rezpegaldesleukin Rights as Eli Lilly Deal Ends >NKTR

By Colin Kellaher

Nektar Therapeutics on Thursday said it would regain full rights to rezpegaldesleukin from partner Eli Lilly & Co., which is ending a licensing agreement following the failure of the compound in a Phase 2 study in systemic lupus erythematosus.

San Francisco-based Nektar said it plans to work quickly to initiate a Phase 2b…

Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

News

This feature is available for all the players and this feature will make the whole gaming experience exciting and unforgettable for the players. This...

News

With other methods of payment, the cost of the conversion is passed onto the player and any winnings generated from that method are converted...

News

If, however, you’re using an alternative banking method, you can click on the ‘Go to Alternative banking’ link to be directed to the page...

News

There are bonus terms and conditions that players must fulfil and all money received is forfeited when they end their active gaming session. Once...